Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
AstraZeneca
Sichuan University
Hoosier Cancer Research Network
Massachusetts General Hospital
Maastricht Radiation Oncology
University of Washington
National Cancer Institute (NCI)
SCRI Development Innovations, LLC
H. Lee Moffitt Cancer Center and Research Institute
Peking University People's Hospital
SCRI Development Innovations, LLC
Alliance for Clinical Trials in Oncology
Stanford University